Dec 9, 2024 · Adstiladrin is a prescription gene therapy used for the treatment of a certain type of bladder cancer. Adstiladrin contains nadofaragene firadenovec-vncg, a non-replicating …

ADSTILADRIN® is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in …

ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non …

Clinical overview Indication: ADSTILADRIN® (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients …

Adstiladrin is also called nadofaragene firadenovec-vncg. Adstiladrin is a gene therapy that uses a non-replicating adenoviral vector (a modified virus that cannot multiply) to deliver a gene to …

Sep 12, 2023 · ADSTILADRIN ® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical gene therapy for the treatment of adult patients with high-risk Bacillus …

Apr 1, 2025 · Abstract On December 16, 2022, the FDA approved the adenoviral vector-based gene therapy nadofaragene firadenovec-vncg (brand name Adstiladrin) for the treatment of …

Nadofaragene firadenovec, sold under the brand name Adstiladrin, is a gene therapy for the treatment of bladder cancer. [1][3][4] It is a non-replicating (cannot multiply in human cells) …

Nov 26, 2025 · So, nadofaragene firadenovec, which is also known as Adstiladrin, is one such gene therapy for bladder cancer that no longer responds to PCG treatment. And importantly, …

Nadofaragene firadenovec-vncg is approved to treat: Non-muscle–invasive bladder cancer with carcinoma in situ. It is used in adults whose cancer does not respond to treatment with bacillus …